Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology
+$0.02 today
- Market cap
- $63.67M
- Beta
- 1.61
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.42
Volume 1.71M
Average 1.16M
CNTX Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Context Therapeutics Inc.NASDAQ: CNTX
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares dips below year-ago levels
Q1 FY2026 weighted avg shares of 95.18M shares fell 0.0% year over year, behind the +30.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 3.6% from the prior quarter. Over 3 fiscal years it compounded at +81.3% a year.
Context
- Weighted avg shares increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -0.0% toward the trailing-twelve-month pace of +30.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 95.19M USD
- Year-over-year change
- +62.9%
- 4-year CAGR
- +140.7%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 95.19M | +62.9% |
| FY2024 | 2024-12-31 | 58.42M | +265.9% |
| FY2023 | 2023-12-31 | 15.97M | +0.0% |
| FY2022 | 2022-12-31 | 15.97M | +463.4% |
| FY2021 | 2021-12-31 | 2.83M | — |
Weighted Avg Shares vs competitors
How CNTX compares with its peers on the latest reported figures
- CNTX's LTM Mar 2026 weighted avg shares of 94.36M shares is the highest of the 11 companies compared; the peer median is 59.45M shares.
- Its year-over-year change of +30.6% is the 5th highest of 11, against a peer median of +9.7%.
- Over three fiscal years its annual growth of +81.3% compares with a peer median of +8.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 94.36M | +30.6% | +81.3% | |
| LTM Mar 2026 | 84.8M | +66.7% | +18.0% | |
| LTM Mar 2026 | 74.41M | +4.8% | +1.5% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | 68.95M | +154.8% | +40.1% |
| LTM Mar 2026 | 68.77M | +14.6% | +15.0% | |
| LTM Mar 2026 | 63.24M | +0.8% | +0.9% | |
| FY2025 | 55.66M | +0.8% | +0.4% | |
| LTM Mar 2026 | 41.42M | +1.6% | +2.0% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | 21.01M | +341.4% | +66.1% |
IMAImageneBio Inc | LTM Mar 2026 | 19.79M | -59.0% | -48.8% |
| LTM Mar 2026 | 10.33M | +43.7% | +44.6% | |
| Peer median (excluding CNTX) | 59.45M | +9.7% | +8.5% | |
Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 3.81M | 7.09M | 17.78M | 22.7M | 31.86M |
| Selling, General & Admin | 3.63M | 7.79M | 7.29M | 7.22M | 7.85M |
| Operating Expenses | 10.53M | 15.38M | 25.07M | 29.92M | 39.7M |
| Depreciation & Amortization | 0 | 9.27K | 12.04K | 10.88K | 16.25K |
| EBITDA | (7.44M) | (14.87M) | (23.95M) | (26.71M) | (36.11M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (10.53M) | (15.38M) | (25.07M) | (29.92M) | (39.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 64 | 547.27K | 1.16M | 3.2M | 3.38M |
| Interest Expense | 64.24K | 547.27K | 0 | 0 | 0 |
| Other Income / Expenses | 68.95K | 545.26K | 1.11M | 3.2M | 3.58M |
| Income Before Tax | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.69) | (0.93) | (1.50) | (0.46) | (0.38) |
| EPS (Diluted) | (3.69) | (0.93) | (1.50) | (0.46) | (0.38) |
| Weighted Avg Shares | 2.83M | 15.97M | 15.97M | 58.42M | 95.19M |
| Weighted Avg Shares (Diluted) | 2.83M | 15.97M | 15.97M | 58.42M | 95.19M |
Context Therapeutics Inc.
NASDAQ:CNTX
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.